References
- Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
- Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
- Bartlett NL, Wilson WH, Jung SH, et al. Dose-Adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-Cell lymphoma: Clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799.
- Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416.
- Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e617.
- Puckrin R, Ghosh S, Peters A, et al. Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. Leukemia & Lymphoma. 2021;1–8. doi:10.1080/10428194.2021.1992762.
- Danesi R, Fogli S, Gennari A, et al. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet. 2002;41(6):431–444.
- Menna P, Salvatorelli E. Primary prevention strategies for anthracycline cardiotoxicity: a brief overview. Chemotherapy. 2017;62(3):159–168.
- Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18(21):3633–3642.
- Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017–3024.
- Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with burkitt's lymphoma. N Engl J Med. 2013;369(20):1915–1925.
- Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of Risk-Adapted therapy with Dose-Adjusted EPOCH-R in adults with untreated burkitt lymphoma. J Clin Oncol. 2020;38(22):2519–2529.
- Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet (London, England). 2019;394(10216):2271–2281.
- Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. The Lancet Oncology. 2015;16(5):541–549.
- Younes A, Sehn LH, Johnson P, PHOENIX investigators, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in Non-Germinal center B-Cell diffuse large B-Cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295.
- Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-Type diffuse large B-Cell lymphoma. J Clin Oncol. 2021;39(12):1317–1328.
- Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-Cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol. 2021;39(12):1329–1338.
- Westin JR, Nastoupil LJ, Fayad L, et al. Smart start: Rituximab, lenalidomide, and ibrutinib alone and in combination with standard chemotherapy for patients with newly diagnosed diffuse large B-Cell lymphoma: Final phase II results. Blood. 2019;134(Supplement_1):1581–1581.
- Melani C, Lakhotia R, Pittaluga S, et al. Phase 1b/2 study of vipor (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed/refractory B-Cell lymphoma: Safety, efficacy and molecular analysis. Blood. 2020;136(Supplement 1):44–45.